RTW Biotech Opportunities (LSE:RTW) Change In Receivables: $0.0 Mil (TTM As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LSE:RTW RTW Biotech Opportunities Ltd LSE:RTW
40 GF Score
Price $2.51
! 2 Warning Signs
View Full Analysis

What is RTW Biotech Opportunities Change In Receivables?

RTW Biotech Opportunities LSE:RTW +0.80% 40 Change In Receivables is $0.0 Mil as of Dec. 2025. GuruFocus rates LSE:RTW with a GF Score™ of 40/100. The stock has 2 warning signs investors should review.

RTW Biotech Opportunities's change in receivables for the quarter that ended in Dec. 2025 was $0.0 Mil. It means RTW Biotech Opportunities's Accounts Receivable stayed the same from Jun. 2025 to Dec. 2025 .

RTW Biotech Opportunities's change in receivables for the fiscal year that ended in Dec. 2025 was $0.0 Mil. It means RTW Biotech Opportunities's Accounts Receivable stayed the same from Dec. 2024 to Dec. 2025 .

RTW Biotech Opportunities's Accounts Receivable for the quarter that ended in Dec. 2025 was $0.0 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. RTW Biotech Opportunities's Days Sales Outstanding for the six months ended in Dec. 2025 was 0.00.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. RTW Biotech Opportunities's liquidation value for the six months ended in Dec. 2025 was $-197.8 Mil.

RTW Biotech Opportunities  (LSE:RTW) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

RTW Biotech Opportunities's Days Sales Outstanding for the quarter that ended in Dec. 2025 is calculated as:

Days Sales Outstanding
=Accounts Receivable/Revenue*Days in Period
=0/288.47*91
=0.00

2. In Ben Graham's calculation of liquidation value, RTW Biotech Opportunities's accounts receivable are only considered to be worth 75% of book value:

RTW Biotech Opportunities's liquidation value for the quarter that ended in Dec. 2025 is calculated as:

Liquidation Value
=Cash, Cash Equivalents, Marketable Securities-Total Liabilities+(0.75 * Accounts Receivable)+(0.5 * Total Inventories)
=5.986-203.819+0.75 * 0+0.5 * 0
=-197.8

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RTW Biotech Opportunities Change In Receivables Related Terms

RTW Biotech Opportunities Change In Receivables Historical Data

* Premium members only.

The historical data trend for RTW Biotech Opportunities's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

RTW Biotech Opportunities Change In Receivables Chart

RTW Biotech Opportunities Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Change In Receivables
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

RTW Biotech Opportunities Semi-Annual Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Change In Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
LSE:RTW
40GF Score
RTW Biotech Opportunities Ltd LSE:RTW
Change In Receivables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

RTW Biotech Opportunities Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Change In Receivables →
What does a Change In Receivables of $0.0 Mil mean?
RTW Biotech Opportunities (LSE:RTW) has a Change In Receivables of $0.0 Mil as of Dec. 2025. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for RTW Biotech Opportunities and its competitors.
Is RTW Biotech Opportunities' Change In Receivables too high?
RTW Biotech Opportunities' current Change In Receivables is $0.0 Mil. Overall, RTW Biotech Opportunities has a GF Score™ of 40/100, reflecting its overall financial health beyond just this single metric.
How does RTW Biotech Opportunities' Change In Receivables compare to BLK and BX?
RTW Biotech Opportunities' Change In Receivables of $0.0 Mil can be compared against companies in the Asset Management industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for an Asset Management company?
A good Change In Receivables depends on the Asset Management industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for RTW Biotech Opportunities and its competitors. RTW Biotech Opportunities's current Change In Receivables is $0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RTW Biotech Opportunities stock overvalued right now?
RTW Biotech Opportunities (LSE:RTW) has a current Change In Receivables of $0.0 Mil. The current Change In Receivables is $0.0 Mil. RTW Biotech Opportunities' overall GF Score™ is 40/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For RTW Biotech Opportunities (LSE:RTW), the current Change In Receivables is $0.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

RTW Biotech Opportunities Business Description

Address St Julian’s Avenue, 1st Floor, Royal Chambers, St Peter Port, GGY, GY1 3JX
RTW Biotech Opportunities Ltd is a life sciences and investment fund focused on identifying transformative assets with high growth potential across the biopharma and medtech sectors. It is powering medical breakthroughs that have the potential to transform the wellbeing of people around the world. Its portfolio includes Neurology, Oncology, Inflammation, Cardiovascular, Metabolic, Pulmonary, Ophthalmology, Rare Disease, and Other. Geographically it operates in USA & Canada, the Rest of World, and UK & EU, with the majority of the revenue deriving from USA & Canada.
40GF Score

Get the complete analysis for LSE:RTW

Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.51
Price